Teacher Retirement System of Texas Purchases Shares of 10,434 Prothena Co. plc (NASDAQ:PRTA)

Teacher Retirement System of Texas acquired a new position in Prothena Co. plc (NASDAQ:PRTA) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 10,434 shares of the biotechnology company’s stock, valued at approximately $145,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Intech Investment Management LLC bought a new position in shares of Prothena during the 3rd quarter worth approximately $210,000. The Manufacturers Life Insurance Company grew its holdings in shares of Prothena by 3.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 86,071 shares of the biotechnology company’s stock worth $1,440,000 after purchasing an additional 3,163 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Prothena by 44.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 55,842 shares of the biotechnology company’s stock worth $934,000 after purchasing an additional 17,230 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Prothena by 1,122.9% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,748 shares of the biotechnology company’s stock valued at $8,812,000 after purchasing an additional 483,673 shares during the last quarter. Finally, Wellington Management Group LLP boosted its position in Prothena by 14.8% in the third quarter. Wellington Management Group LLP now owns 4,178,788 shares of the biotechnology company’s stock valued at $69,911,000 after buying an additional 539,359 shares in the last quarter. 97.08% of the stock is owned by institutional investors.

Prothena Stock Up 3.4 %

PRTA stock opened at $12.14 on Thursday. The company has a market cap of $653.46 million, a P/E ratio of -5.28 and a beta of -0.02. Prothena Co. plc has a twelve month low of $11.42 and a twelve month high of $25.42. The business has a fifty day moving average of $14.20 and a 200-day moving average of $15.38.

Prothena (NASDAQ:PRTA) last issued its earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.06). Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The business had revenue of $2.12 million during the quarter, compared to the consensus estimate of $7.53 million. As a group, equities research analysts anticipate that Prothena Co. plc will post -4.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

PRTA has been the subject of several recent analyst reports. Chardan Capital reaffirmed a “buy” rating and set a $40.00 price objective on shares of Prothena in a report on Friday, February 21st. Royal Bank of Canada dropped their price target on Prothena from $24.00 to $20.00 and set a “sector perform” rating for the company in a report on Friday, February 21st. Oppenheimer boosted their price objective on Prothena from $58.00 to $62.00 and gave the stock an “outperform” rating in a research note on Friday, February 7th. Piper Sandler raised their target price on Prothena from $94.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Prothena in a report on Friday, February 21st. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.00.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.